340B Practice Fact SheetBMS has announced 340B practice updates that will apply to all 340B covered entity types. BMS remains committed toworking with covered entities to protect the integrity of the 340B program and to help ensure that uninsured and lowincome patients can access the medications they need at the 340B price. BMS will continue to apply its practice as
circumstances require to fulfill applicable legal obligations and support practice requirements.

Questions regarding these 340B practice updates may be submitted to BMS340B@bms.com.
Contract Pharmacy Practice
BMS will recognize up to four designated 340B contract pharmacy locations for each 340B covered entity that does
not have its own entity-owned pharmacy: effective July 1, 2024, one for certain of our covered outpatient drugs(non-IMiDs), a second for our immunomodulatory drugs (IMiDs) (Revlimid®, Pomalyst®, and Thalomid®), and a thirdfor Camzyos®; and, effective October 1, 2024, a fourth for Krazati®. BMS will continue to offer 340B prices on drugs
sold to covered entities and delivered to their entity-owned pharmacies, in compliance with applicable law. To
ensure transparency and program integrity at designated contract pharmacies, BMS expects that all dispensing to340B-eligible patients will occur at the properly designated contract pharmacy location(s), and that 340B drugs will
be shipped directly to that location either by BMS or an authorized distributor.
Non-IMiDs. BMS will permit each covered entity that lacks its own entity-owned pharmacy to select and utilize asingle designated contract pharmacy location for non-IMiD products. The non-IMiD contract pharmacy location
selected by the covered entity need not be the same pharmacy as the IMiD, Camzyos®, or Krazati® contract
pharmacy location, although it may be. Entities that choose to access non-IMiDs at 340B prices at a non-IMiDdesignated contract pharmacy location will submit claim information to BMS, via 340B ESP™ platform, subject tothe applicable BMS Terms of Use. Only one 340B purchase may occur on a single eligible non-IMiD prescription. Only
one covered entity may claim the 340B discount on a given dispense.
IMiDs. 340B covered entities that are not already part of the IMiD limited distribution network will have the option
to access the IMiDs at 340B prices through one in-network IMiD-designated specialty contract dispensing pharmacy
location per applicable covered entity. This update does not amend or expand the IMiD limited distribution networkof pharmacies and will not affect access to the IMiDs for any patient. Patients receiving IMiDs will still be able toreceive their medications from the same dispensaries. Entities that choose to access IMiDs at 340B prices at an IMiDdesignated specialty contract pharmacy location will submit claim information to BMS directly, subject to theapplicable BMS Terms of Use. Only one 340B purchase may occur on a single eligible IMiD prescription. Only one
covered entity may claim the 340B discount on a given dispense.
Camzyos®. 340B covered entities that are not already part of the Camzyos® limited distribution network will havethe option to access Camzyos® at 340B prices through one in-network Camzyos®-designated specialty contract
dispensing pharmacy location per applicable covered entity. Entities that choose to access Camzyos® at 340B prices
at a Camzyos®-designated contract pharmacy location will submit claim information to BMS, via 340B ESP™
platform, subject to the applicable BMS Terms of Use. Only one 340B purchase may occur on a single eligible
Camzyos® prescription. Only one covered entity may claim the 340B discount on a given dispense.

Krazati®. 340B covered entities that are not already part of the Krazati® specialty distribution network will havethe option to access Krazati® at 340B prices through one in-network Krazati®-designated specialty contract
dispensing pharmacy location per applicable covered entity. Entities that choose to access Krazati® at 340B prices
at a Krazati®-designated contract pharmacy location will submit claim information to BMS, via 340B ESP™ platform,
subject to the applicable BMS Terms of Use. Only one covered entity may claim the 340B discount on a given
dispense.

2© 2023 Bristol Myers Squibb Company